Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia

Ching Hon Pui; Michael J. Schell; Susana C. Raimondi; David R. Head; Gaston K. Rivera; William M. Crist; Frederick G. Behm; Michael J. Borowitz; Jonathan J. Shuster; Vita J. Land; C. Philip Steuber; D. Jeanette Pullen; Teresa J. Vietti; Hiroyuki Tsuchiya; Norio Asou; Masahiko Watanabe; Akihiro Shimosaka; Kiyoshi Takatsuki; Ichiro Matsuda; Susan R. Wiersma; Jorge A. Ortega; Eugene Sobel; Kenneth I. Weinberg

doi:10.1056/NEJM199111073251914

Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia

Ching Hon Pui, Michael J. Schell, Susana C. Raimondi, David R. Head, Gaston K. Rivera, William M. Crist, Frederick G. Behm, Michael J. Borowitz, Jonathan J. Shuster, Vita J. Land, C. Philip Steuber, D. Jeanette Pullen, Teresa J. Vietti, Hiroyuki Tsuchiya, Norio Asou, Masahiko Watanabe, Akihiro Shimosaka, Kiyoshi Takatsuki, Ichiro Matsuda, Susan R. WiersmaJorge A. Ortega, Eugene Sobel, Kenneth I. Weinberg

Research output: Contribution to journal › Letter › peer-review

29 Scopus citations

Abstract

To the Editor: Wiersma and coworkers (March 21 issue)¹ found that expression of myeloid antigens (CD14 [My4], CD13 [My7], and CD33 [My9]) was an independent predictor of a poor outcome among 236 children with acute lymphoblastic leukemia (ALL) treated according to at least five different clinical protocols. This result contrasts sharply with our recent observation that myeloid-associated antigens lacked prognostic value in 267 children treated intensively with similar regimens of combination chemotherapy.² As Wiersma et al. suggest, differences in definitions of myeloid-antigen expression, immunophenotyping methods, study populations, treatment regimens, or a combination of these factors may explain the discordant results.

Original language	English (US)
Pages (from-to)	1378-1382
Number of pages	5
Journal	New England Journal of Medicine
Volume	325
Issue number	19
DOIs	https://doi.org/10.1056/NEJM199111073251914
State	Published - Nov 7 1991
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM199111073251914

Cite this

Pui, C. H., Schell, M. J., Raimondi, S. C., Head, D. R., Rivera, G. K., Crist, W. M., Behm, F. G., Borowitz, M. J., Shuster, J. J., Land, V. J., Steuber, C. P., Pullen, D. J., Vietti, T. J., Tsuchiya, H., Asou, N., Watanabe, M., Shimosaka, A., Takatsuki, K., Matsuda, I., ... Weinberg, K. I. (1991). Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 325(19), 1378-1382. https://doi.org/10.1056/NEJM199111073251914

Pui, CH, Schell, MJ, Raimondi, SC, Head, DR, Rivera, GK, Crist, WM, Behm, FG, Borowitz, MJ, Shuster, JJ, Land, VJ, Steuber, CP, Pullen, DJ, Vietti, TJ, Tsuchiya, H, Asou, N, Watanabe, M, Shimosaka, A, Takatsuki, K, Matsuda, I, Wiersma, SR, Ortega, JA, Sobel, E & Weinberg, KI 1991, 'Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia', New England Journal of Medicine, vol. 325, no. 19, pp. 1378-1382. https://doi.org/10.1056/NEJM199111073251914

@article{2f19e100ea7948aeb829de028886f78d,

title = "Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia",

abstract = "To the Editor: Wiersma and coworkers (March 21 issue)1 found that expression of myeloid antigens (CD14 [My4], CD13 [My7], and CD33 [My9]) was an independent predictor of a poor outcome among 236 children with acute lymphoblastic leukemia (ALL) treated according to at least five different clinical protocols. This result contrasts sharply with our recent observation that myeloid-associated antigens lacked prognostic value in 267 children treated intensively with similar regimens of combination chemotherapy.2 As Wiersma et al. suggest, differences in definitions of myeloid-antigen expression, immunophenotyping methods, study populations, treatment regimens, or a combination of these factors may explain the discordant results.",

author = "Pui, {Ching Hon} and Schell, {Michael J.} and Raimondi, {Susana C.} and Head, {David R.} and Rivera, {Gaston K.} and Crist, {William M.} and Behm, {Frederick G.} and Borowitz, {Michael J.} and Shuster, {Jonathan J.} and Land, {Vita J.} and Steuber, {C. Philip} and Pullen, {D. Jeanette} and Vietti, {Teresa J.} and Hiroyuki Tsuchiya and Norio Asou and Masahiko Watanabe and Akihiro Shimosaka and Kiyoshi Takatsuki and Ichiro Matsuda and Wiersma, {Susan R.} and Ortega, {Jorge A.} and Eugene Sobel and Weinberg, {Kenneth I.}",

year = "1991",

month = nov,

day = "7",

doi = "10.1056/NEJM199111073251914",

language = "English (US)",

volume = "325",

pages = "1378--1382",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "19",

}

TY - JOUR

T1 - Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia

AU - Pui, Ching Hon

AU - Schell, Michael J.

AU - Raimondi, Susana C.

AU - Head, David R.

AU - Rivera, Gaston K.

AU - Crist, William M.

AU - Behm, Frederick G.

AU - Borowitz, Michael J.

AU - Shuster, Jonathan J.

AU - Land, Vita J.

AU - Steuber, C. Philip

AU - Pullen, D. Jeanette

AU - Vietti, Teresa J.

AU - Tsuchiya, Hiroyuki

AU - Asou, Norio

AU - Watanabe, Masahiko

AU - Shimosaka, Akihiro

AU - Takatsuki, Kiyoshi

AU - Matsuda, Ichiro

AU - Wiersma, Susan R.

AU - Ortega, Jorge A.

AU - Sobel, Eugene

AU - Weinberg, Kenneth I.

PY - 1991/11/7

Y1 - 1991/11/7

N2 - To the Editor: Wiersma and coworkers (March 21 issue)1 found that expression of myeloid antigens (CD14 [My4], CD13 [My7], and CD33 [My9]) was an independent predictor of a poor outcome among 236 children with acute lymphoblastic leukemia (ALL) treated according to at least five different clinical protocols. This result contrasts sharply with our recent observation that myeloid-associated antigens lacked prognostic value in 267 children treated intensively with similar regimens of combination chemotherapy.2 As Wiersma et al. suggest, differences in definitions of myeloid-antigen expression, immunophenotyping methods, study populations, treatment regimens, or a combination of these factors may explain the discordant results.

AB - To the Editor: Wiersma and coworkers (March 21 issue)1 found that expression of myeloid antigens (CD14 [My4], CD13 [My7], and CD33 [My9]) was an independent predictor of a poor outcome among 236 children with acute lymphoblastic leukemia (ALL) treated according to at least five different clinical protocols. This result contrasts sharply with our recent observation that myeloid-associated antigens lacked prognostic value in 267 children treated intensively with similar regimens of combination chemotherapy.2 As Wiersma et al. suggest, differences in definitions of myeloid-antigen expression, immunophenotyping methods, study populations, treatment regimens, or a combination of these factors may explain the discordant results.

UR - http://www.scopus.com/inward/record.url?scp=0025944842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025944842&partnerID=8YFLogxK

U2 - 10.1056/NEJM199111073251914

DO - 10.1056/NEJM199111073251914

M3 - Letter

C2 - 1833646

AN - SCOPUS:0025944842

SN - 0028-4793

VL - 325

SP - 1378

EP - 1382

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 19

ER -

Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this